#EVGN hashtag - Bluesky

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock Evogene (NASDAQ: EVGN) subsidiary Casterra reported successful commercial field trials across 74 hectares in Bahia, Brazil, showing mechanized, low-input castor farming can be economically viable for castor oil feedstock. Trials included 64 hectares rainfed, 10 hectares irrigated, and recorded 382 mm rainfall.Casterra plans a 2026 push via a local subsidiary, strategic partnerships with castor oil producers, and expanded trials across multiple Brazilian states to support castor as a scalable biofuel feedstock.

3 days ago

#EVGN Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

www.stocktitan.net/news/EVGN/casterra-annou...

0 0 0 0

AI drug designer Evogene slashes costs as it sells side businesses Operating expenses fell to $13.8M in 2025 and net loss shrank to $7.8M, as Evogene sold Lavie Bio and Biomica and raised $3.4M from warrant exercise.

4 weeks ago

#EVGN Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/EVGN/evogene-report...

0 0 0 0

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders Evogene (NASDAQ: EVGN) and Unravel Biosciences announced a collaboration on January 7, 2026 to discover and optimize a first-in-class small-molecule therapy aimed at restoring myelin and reversing neurological damage in demyelinating disorders including multiple sclerosis.The program combines Evogene's ChemPass AI generative chemistry platform with Unravel's BioNAV predictive biology and Living Molecular Twins patient-derived data to design brain-penetrant inhibitors against a novel demyelination target discovered by Unravel. Work will use in vitro, in vivo, and in silico outcome simulation to advance lead candidates toward potential clinical development.

2 months ago

#EVGN Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

www.stocktitan.net/news/EVGN/evogene-and-un...

0 0 0 0

Evogene Reports Second Quarter 2025 Financial Results Evogene (NASDAQ: EVGN) reported Q2 2025 financial results, highlighting its strategic transformation focused on ChemPass AI, its platform for AI-driven small molecule discovery. The company reported H1 2025 revenues of $3.2 million, up from $2.3 million in H1 2024, while reducing operating expenses to $7.7 million from $11.1 million year-over-year.Key developments include the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL for $18.71 million, completion of a major restructuring with a 30% workforce reduction at Evogene and 40% at AgPlenus, and raising $4.4 million through ATM facility. The company's cash position stood at $11.7 million as of June 30, 2025, with an 18-month operational runway post-ICL transaction.

7 months ago

#EVGN Evogene Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/EVGN/evogene-report...

0 0 0 0

Breakthrough: AI-Driven Drug Discovery Partnership Targets Tyrosinemia and Gout Treatment Novel AI platform combines with molecular expertise to tackle metabolic diseases. Partnership targets multiple conditions including Tyrosinemia and Gout. Learn more.

7 months ago

#EVGN Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

www.stocktitan.net/news/EVGN/evogene-and-pr...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Leading Indicators, Wednesday July 30, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend with AROON Oscillator, Wed Jul 30th - #RPD #QSI #PHLT #OM #NWBI #MBIN #LFCR #KARO #IBCP #HAFC #SAGE #GAIN #FCBC #EVGN #DIBS #CERS #BEAT #AARD #VFS #TDOC #SCL #TBRG - More: crystalequityresearch.com/leading-indi... - #smallcap

1 0 0 0

Agricultural AI Pioneer Evogene Sells Lavie Bio to ICL in Major Biotech Deal Evogene transfers MicroBoost AI platform and ag-biologicals subsidiary to ICL Group, advancing sustainable agriculture innovation. Get exclusive deal insights.

8 months ago

#EVGN #ICL Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

www.stocktitan.net/news/EVGN/evogene-announ...

0 0 0 0

9 months ago

🚀 Exciting times for #EVGN! Trading at $1.48 with a bullish MACD and strategic partnerships on the horizon, this stock is poised for potential gains. Consider a cautious long position with targets at $1.55 & $1.60. Will it soar? Keep an eye on volume! 📈 #FeetrAI

0 0 0 0

9 months ago

🚀 Exciting times for #EVGN! Trading at $1.45, short-term bullish momentum with 10-day SMA leading the way. But watch out—regulatory challenges and market tensions loom large. Consider a short position targeting $1.35 & $1.25, stop loss at $1.55. Stay alert! 📉 #FeetrAI

0 0 0 0

9 months ago

🚀 Exciting times for #EVGN! With bullish momentum and strategic partnerships, this biotech gem is on the rise. Current price at $1.525 above key averages, targeting $1.70 & $1.90. Caution: low volume may mean volatility. Stay alert for market trends! 📈 #FeetrAI #Stocks

0 0 0 0

9 months ago

🚀 Exciting times for #EVGN! With strategic moves and partnerships, this biotech stock is showing bullish momentum. Current price: $1.46, above 10-day SMA. Enter at $1.45, target $1.60/$1.75, stop loss $1.35. Watch for catalysts! 📈 #Biotech #Stocks #FeetrAI

0 0 0 0

@smcapstrategist.bsky.social

9 months ago

🚀 Exciting times for #EVGN! With a strong bullish momentum, it's trading at $1.99, well above its 10-day SMA of $1.22. Despite an overbought RSI of 87.94, the MACD suggests more upside! 📈 Targeting $2.20 & $2.35 with caution advised. Stay tuned for market moves! #Stocks #FeetrAI

0 0 0 0

Small Cap Strategist

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jun 10th - #RXRX #NVTS #IOVA #RIG #QUBT #TDOC #SPCE #SEDG #RGTI #PLUG #NAK #TGB #MGNX #APLD #KLTO #AREB #EVGN #BORR #ESPR #BTCS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

9 months ago

JUST IN: ( NASDAQ: #EVGN ) Closing Bell Buzz: Small Caps, Big Moves

0 0 0 0

9 months ago

BREAKING NEWS: ( NASDAQ: #EVGN ) Evogene Ltd. (NASDAQ: EVGN) Sees Notable Increase in Tuesday Morning Market Activity

0 0 0 0

9 months ago

NEWS: ( NASDAQ: #EVGN ) Evogene and Google Cloud Unveil Breakthrough Foundation Model for Generative Small Molecule Design

0 0 0 0

9 months ago

Just In: ( NASDAQ: #EVGN ) Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

0 0 0 0

Evogene's New AI Model Achieves 90% Precision in Drug Discovery, Crushing Traditional 29% Success Rate Revolutionary AI foundation model achieves 90% precision in molecule design, transforming drug and agritech discovery. See how this Google Cloud collaboration changes R&D landscape.

9 months ago

#EVGN Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

www.stocktitan.net/news/EVGN/evogene-announ...

0 0 0 0

Evogene Earnings: Revenue Drops to $2.4M While $15.25M ICL Deal Signals Major Strategic Shift Q1 results reveal strategic pivot to pharma AI tech while ICL acquires Lavie Bio operations for $15.25M. See how Evogene plans to accelerate monetization and growth. Get insights.

10 months ago

#EVGN Evogene Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/EVGN/evogene-report...

0 0 0 0

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results Evogene (NASDAQ: EVGN) reported its Q4 and full-year 2024 financial results, showing significant revenue growth to $8.5 million in 2024, up from $5.6 million in 2023. The increase was primarily driven by AgPlenus' Bayer collaboration and Casterra's seed sales.The company reduced its net loss to $18.1 million in 2024 from $26.0 million in 2023, while R&D expenses decreased to $16.6 million from $20.8 million. Cash position stood at $15.3 million as of December 31, 2024, with reduced cash usage of $10.4 million in 2024.Strategic highlights include:Implementation of a 30% headcount reduction planFocus on ChemPass AI tech-engine for drug discoveryPlans for subsidiary exit eventsExpansion of Casterra's castor seed business with significant delivery increases

1 year ago

#EVGN Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/EVGN/evogene-report...

0 0 0 0

Revolutionary Discovery: New Weapon Against €1.2B Wheat Disease Threat Unveiled AgPlenus achieves major breakthrough in fighting Septoria tritici blotch with novel Mode of Action discovery, targeting €1.2B European wheat fungicide market.

1 year ago

#EVGN AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

www.stocktitan.net/news/EVGN/ag-plenus-anno...

0 0 0 0

1 year ago

#EVGN Evogene Reports Third Quarter 2024 Financial Results

www.stocktitan.net/news/EVGN/evogene-report...

0 0 0 0

1 year ago

#EVGN Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

www.stocktitan.net/news/EVGN/lavie-bio-adva...

0 0 0 0

1 year ago

News; ( NASDAQ: #EVGN ) Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

#StockMarket #News

1 0 0 0